-
13164-10A dual inhibitor of mPGES-1 (IC<sub>50 </sub>= 1.3 &muM) and 5-LO (IC<sub>50</sub> = 1.0 &muM) effectively inhibits PGE2 and LT synthesis in both cell free and intact cell assays.
-
13164-5A dual inhibitor of mPGES-1 (IC<sub>50 </sub>= 1.3 &muM) and 5-LO (IC<sub>50</sub> = 1.0 &muM) effectively inhibits PGE2 and LT synthesis in both cell free and intact cell assays.
-
13181-1A potent and selective inhibitor of sPLA2 that exhibits 95% inhibition (XI(50)=0.003) of sPLA2 without affecting the activities of cPLA2 or iPLA2.
-
13181-10A potent and selective inhibitor of sPLA2 that exhibits 95% inhibition (XI(50)=0.003) of sPLA2 without affecting the activities of cPLA2 or iPLA2.
-
13181-5A potent and selective inhibitor of sPLA2 that exhibits 95% inhibition (XI(50)=0.003) of sPLA2 without affecting the activities of cPLA2 or iPLA2.
-
13181-50A potent and selective inhibitor of sPLA2 that exhibits 95% inhibition (XI(50)=0.003) of sPLA2 without affecting the activities of cPLA2 or iPLA2.
-
10009797-1An activator of SIRT1 that decreases TNF-&alpha levels from 325 pg/ml (control) to 104 and 53 pg/ml at 20 and 60 µM, respectively exhibits a significant dose-dependent effect on fat mobilization in differentiated adipocytes.
-
10009797-10An activator of SIRT1 that decreases TNF-&alpha levels from 325 pg/ml (control) to 104 and 53 pg/ml at 20 and 60 µM, respectively exhibits a significant dose-dependent effect on fat mobilization in differentiated adipocytes.
-
10009797-25An activator of SIRT1 that decreases TNF-&alpha levels from 325 pg/ml (control) to 104 and 53 pg/ml at 20 and 60 µM, respectively exhibits a significant dose-dependent effect on fat mobilization in differentiated adipocytes.
-
10009797-5An activator of SIRT1 that decreases TNF-&alpha levels from 325 pg/ml (control) to 104 and 53 pg/ml at 20 and 60 µM, respectively exhibits a significant dose-dependent effect on fat mobilization in differentiated adipocytes.
-
10012536-1A selective PPARd agonist that acts as a partial agonist (EC50 = 53 nM) in transactivation assays and as a full agonist (EC50 = 30 nM) in the oxidation of free fatty acid increases HDL levels, decreases LDL and TG levels, and improves insulin
-
10012536-10A selective PPARd agonist that acts as a partial agonist (EC50 = 53 nM) in transactivation assays and as a full agonist (EC50 = 30 nM) in the oxidation of free fatty acid increases HDL levels, decreases LDL and TG levels, and improves insulin